Chronic ethanol sensitizes the liver to endotoxin via effects on endothelial nitric oxide synthase regulation.
In vivo studies have shown that chronic alcohol consumption sensitizes the liver to endotoxemic shock, leading to liver microcirculation disruption. In the present study, we investigated the molecular mechanisms involved, focusing on endothelial nitric oxide synthase (eNOS) activity and regulation, which represents one of the major vasodilatory pathways. Male Sprague-Dawley rats were fed an alcohol liquid diet or a control isocaloric diet for 5 weeks. Priming effects of ethanol were studied in a model with or without a 24-h LPS treatment (1 mg/kg body weight). At the end of the diet, liver tissue was harvested for western blot, reverse transcriptase-PCR, histological analysis, and immunostaining and blood for serum alanine aminotransferase analysis. Chronic ethanol and LPS alone induced a mild hepatitis and infiltration, respectively. Combined, LPS and chronic ethanol feeding showed a synergistic effect on the liver, leading to extensive steatohepatitis with extensive focal necrosis associated with significantly higher levels of serum ALT. Chronic ethanol and LPS significantly inhibited eNOS activity, but exerted their effects through different mechanisms. Caveolin-1, an eNOS inhibitory protein, was upregulated after LPS and chronic alcohol consumption. Additionally, chronic alcohol consumption down-regulated endothelin B receptor, eNOS protein levels, and eNOS phosphorylation. In conclusion, chronic ethanol consumption and LPS share a similar pathophysiology and both lead to the impairment of eNOS activity, but through distinct molecular mechanisms. The presence of focal necrosis in a mild stress model could provide a good animal study to investigate the advanced stages of alcoholic liver diseases.
Karaa
Amel
A
Department of Biology, University of North Carolina, Charlotte, North Carolina 28223, USA.
Kamoun
Walid S
WS
Clemens
Mark G
MG
D000410:Alanine Transaminase / Q000097:blood; D000428:Alcohol Drinking; D000818:Animals; D015153:Blotting, Western; D001835:Body Weight; D015536:Down-Regulation; D004357:Drug Synergism; D019332:Endothelin-1 / Q000378:metabolism; D004731:Endotoxins / Q000378:metabolism*; D000431:Ethanol / Q000008:administration & dosage* / Q000494:pharmacology; D015971:Gene Expression Regulation, Enzymologic; D006505:Hepatitis; D007150:Immunohistochemistry; D008070:Lipopolysaccharides / Q000378:metabolism; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008297:Male; D009336:Necrosis; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism*; D010766:Phosphorylation; D012313:RNA / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D044023:Receptor, Endothelin B / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
D019332:Endothelin-1; D004731:Endotoxins; D008070:Lipopolysaccharides; D012333:RNA, Messenger; D044023:Receptor, Endothelin B; D000431:Ethanol; D012313:RNA; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; D000410:Alanine Transaminase